Tyandil

Tyandil Uses, Dosage, Side Effects, Food Interaction and all others data.

Tyandil dilates arterioles and large coronary arteries by opening the potassium channels, and stimulates guanylate cyclase causing venous vasodilatation. It therefore reduces preload and afterload, and improves coronary blood flow.

Tyandil is a potassium channel opener with nitrovasodilator (NO donor) actions, making it both an arterial and a venous dilator . It causes sustained dilation of both the arterial resistance and conductive vessels that increases coronary blood flow, however the effect of the drug on coronary arteries does not involve the coronary steal phenomenon . Activation of potassium channels lead to hyperpolarization of the smooth muscle cells, followed by arterial dilation and afterload reduction. Tyandil is shown to increase pooling in the capacitance vessels with a decrease in preload through relaxing the venous vascular system. Overall, improved blood flow and reduced infarct size are achieved through reduction of end-diastolix pressure and decreased extravascular component of vascular resistance . Open studies showed the effectiveness of nicorandil treatment on various types of angina pectoris .

Trade Name Tyandil
Generic Nicorandil
Nicorandil Other Names Nicorandil, Nicorandilum
Type Tablet
Formula C8H9N3O4
Weight Average: 211.177
Monoisotopic: 211.059305782
Protein binding

Nicorandil is about 25% bound to human albumin and other plasma proteins .

Groups Approved, Investigational
Therapeutic Class Potassium-channel activator
Manufacturer Tycoon Pharmaceuticals Pvt Ltd
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Tyandil
Tyandil

Uses

Tyandil is used for the prevention and long-term treatment of angina pectoris.

Tyandil is also used to associated treatment for these conditions: Angina Pectoris

How Tyandil works

Tyandil mediates its therapeutic efficacy via two main mechanisms. Tyandil is an activator and opener of ATP-sensitive (ATP-dependent) potassium channels (KATP channels) that are composed of Kir6.x-type subunits and sulfonylurea receptor (SUR) subunits. Tyandil binding sites are located in the sulfonylurea receptor 2 (SUR2) in the ATP-sensitive potassium channel , which are regulatory subunits of the channel that exhibit an ATPase activitiy . There are 2 types of SUR2 subunits (2A/2B) that have identical nucleotide binding domains (NBD), where SUR2A is more predominantly expressed in skeletal and cardiac myocytes and SUR2B in smooth muscle cells . Tyandil more potently activates SUR2B/Kir6.2 than SUR2A/Kir6.2 channels to cause hyperpolarization. ATP-NBD1 interaction influences the channel signalling by nicorandil, and the response of the channel to nicorandil is also facilitated and heightened by the interaction of ATP or ADP with NBD2 . Potentiated activity of ATP-sensitive channels have cardioprotective role by limiting the duration of action potentials and preventing intraceullar calcium overload . This attenuates cellular injury by preserving cellular energetics and ultimately cell survival . KATP channel-dependent membrane hyperpolarization can also lead to vasodilation via reduction in Ca2+ influx through the voltage-gated Ca2+ channels and regulation of intracellular Ca2+ mobilization in smooth muscle cells . Tyandil contain a nitrate moiety in its structure, making it a good dilator of vascular smooth muscle like other nitroglycerin esters . Direct relaxation of venous vascular system arises from NO-donor mediated stimulation of guanylyl cyclase and increased levels of intracellular cyclic GMP (cGMP). Elevated levels of cGMP contributes to the total relaxing effect of nicorandil at higher concentrations of the drug .

Dosage

Tyandil dosage

Adult: The usual therapeutic range is 10 to 20 mg twice daily. The usualstarting dose is 10 mg twice daily, in the morning and in the eveningpreferably, and should be titrated upwards in accordance with patients needs, response andtolerance up to 40 mg twice daily, if necessary. An even lower starting dose of 5 mg twice daily may be used in patients particularly prone to headache.

Eldery: There are nospecial dosage requirements for elderly patients, but as with all medicines the lowest effectivedose should be used. Tyandil should be administered with care, using low startingdosages, in the elderly.

Children: Not recommended. Tyandil should be used withcaution in patients with serious hepatic dysfunction.

Hepatic Impairment: Dose reduction may be necessary.

Side Effects

Headache (usually transitory), flushing, dizziness, nausea, vomiting and weakness. Hypotension and reflex tachycardia at high doses.

Toxicity

Common adverse effects include lethargy, back pain, chest pain, infection, feeling of weakness. In the cardiovascular system, hypotension, increased heart rate in higher doses, palpitations, worsened angina pectoris and vasodilation/flush may be observed. Dyspepsia, nausea, and vomiting may occur as gastrointestinal disorders. Headaches may arise from vasodilation. Other common side effects include myalgia, bronchitis, dyspnoea, and respiratory disorder . Tyandil does not affect fertility of male or female rats, and shows no potential in carcinogenic, mutagenic or genotoxic studies . Oral LD50 values in mouse, rat and dog are 626 mg/kg, 1220 mg/kg and 62.5 mg/kg, respectively .

Precaution

Hypovolaemia, low systolic BP, acute pulmonary oedema, pregnancy. May impair ability to drive or operate machinery.

Interaction

Although no pharmacological and/or pharmacokinetic interaction has been obsen/ed in animal and human studies with Tyandil associated with beta-blockers, calcium antagonists, digoxin, a combination of digoxin/furosemide, rifampicin, and cimetidine, it is not excluded that the drug may nevertheless potentiate the effect of other vasodilators, tricyclic antidepressants and antihypertensive drugs administered concurrently, especially in combination with alcohol.

Volume of Distribution

After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0-1.4 L/kg body weight .

Elimination Route

Following oral administration, nicorandil is well absorbed from the gastrointestinal tract with the oral bioavailability of 75% with the maximum peak plasma concentration (Cmax) reached within 30-60 minutes. The mean Cmax is Cmax then is approximately 300 ng/ml . Steady-state plasma concentrations of nicorandil usually are reached within approximately 96-120 h after twice daily dosing (10 or 20mg) .

Half Life

The elimination half life is approximately 1 hour .

Clearance

The total body clearance is approximately 1.15 L/min .

Elimination Route

The main route of elimination is the kidney with more than 60% of the administered dose was eliminated in the urine 24 hours after dosing . Only approximately 1% of nicorandil is excreted unchanged in the urine, and the remaining compounds are mainly the denitrated metabolite (9%) and its derivatives (e.g. nicotinuric acid 6%, nicotinamide 1%, N-methylnicotinamide < 1% and nicotinic acid < 1%) . Less than 2% of administered dose is excreted through the biliary system .

Pregnancy & Breastfeeding use

Although animal studies have not shown any harmful effect of Tyandil to the foetus, has not been studied in human pregnancy. Use in pregnant women requires that the anticipated benefit be weighed against possible hazard. It is not known whether the drug is excreted in human milk. Caution should be exercised when Tyandil is administered to a nursing mother. Drug interactions: Although no pharmacological and/or pharmacokinetic interaction has been obsen/ed in animal and human studies with Tyandil associated with beta-blockers, calcium antagonists, digoxin, a combination of digoxin/furosemide, rifampicin, and cimetidine, it is not excluded that the drug may nevertheless potentiate the effect of other vasodilators, tricyclic antidepressants and antihypertensive drugs administered concurrently, especially in combination with alcohol.

Contraindication

Tyandil tablet is contra-indicated in patients who have shown hypersensitivity to Tyandil. Use is contra-indicated with cardiogenic shock and acute myocardial infarction with acute left ventricular failure and low filling pressures, in patients with hypotension, and in patients taking phosphodiesterase-5 inhibitors because concurrent use of Tyandil can lead to a serious drop in blood pressure. Warnings and precautions: Tyandil should be used with caution in patients who may have blood volume depletion or in those who present with low systolic blood pressure (below 100 mm Hg). The use of the drug in patients with cardiogenic shock, or acute myocardial infarction with acute left ventricular failure and low filling pressures should be avoided. Tyandil should be discontinued and appropriate measures taken if mouth ulceration, stomatitis or persistent or severe buccal ulcerations, appear. Caution is advised for the use of Tyandil in patients with glaucoma. The hypotensive effect of other vasodilators, tricyclic antidepressants or alcohol can be increased by administration in combination with Tyandil. Therapeutic doses of Tyandil may lower the blood pressure of hypertensive patients and Tyandil therefore, as with other antianginal agents, should be used with care when prescribed with antihypertensive drugs. Animal mutagenicify and carcinogenicity studies have not revealed any adverse effect of Tyandil when used under experimental conditions.

Acute Overdose

ln the case of overdosage, the likely symptomatology may be peripheral vasodilation with a fall in blood pressure and reflex tachycardia. In such an event, monitoring of cardiac function and general supportive measures should be used. If not successful, circulating plasma volume should be increased by substitution of fluid. ln life-threatening situations, administration of vasopressors should be considered.

Storage Condition

Store in a cool and dry place, protected from light.

Innovators Monograph

You find simplified version here Tyandil

*** Taking medicines without doctor's advice can cause long-term problems.
Share